相关临床试验
6
1 进行中
药物批准
9
批准总数
监管机构
2
监管机构数
成立时间
1999
进行中（未招募）
1
16.7%
已完成
3
50.0%
招募中
1
16.7%
终止
1
16.7%
- Formycon AG announced a strategic partnership with ATHOS KG valued at approximately €650 million, marking one of the most significant developments in the German biotech company's history. - The collaboration grants Formycon participation rights in two biosimilar candidates, accelerating time-to-market while reducing clinical and regulatory risk compared to in-house development. - The deal structure includes upfront payments, milestone fees tied to regulatory approvals, and commercial royalties, representing a fundamental shift in Formycon's capital allocation strategy. - Biosimilars command higher margins than generic pharmaceuticals due to sophisticated manufacturing requirements and regulatory complexity, positioning Formycon in an attractive market segment driven by patent expirations and healthcare cost containment.
- Formycon AG and MS Pharma have signed an exclusive licensing and supply agreement for FYB206, a biosimilar candidate to Keytruda (pembrolizumab), covering the Middle East and North Africa region. - FYB206 is approaching the end of its clinical development phase, with primary endpoint results expected in the first quarter of 2026. - The partnership aims to improve access to cancer treatment in a region where Keytruda generates approximately $240 million in sales, representing the highest-selling biologic in MENA. - This collaboration marks the beginning of Formycon's commercial partnering activities for their Keytruda biosimilar, with additional regional agreements planned for the future.
- Formycon AG successfully completed the Technical Proof of Similarity (TPoS) for FYB208, demonstrating high analytical comparability to Dupixent (dupilumab). - The biosimilar candidate targets chronic inflammatory diseases including COPD, asthma, and atopic dermatitis in a market expected to reach over $20 billion by 2030. - Strong preclinical data may enable FYB208 to proceed without a Phase III comparative efficacy study, potentially accelerating development timelines. - The achievement adds another growth driver to Formycon's biosimilar portfolio, which already includes two marketed products and one recently approved candidate.
- Ranivisio® PFS, developed by Bioeq AG and commercialized by Teva, becomes the first Lucentis® biosimilar available in pre-filled syringe format across Europe. - The innovative pre-filled syringe offers improved handling, high dosing accuracy, and reduced preparation time for treating wet age-related macular degeneration and other retinal diseases. - The launch began in France in October 2025, with additional European countries including Germany planned for staggered rollout. - The silicon-oil free syringe technology features low injection pressure and minimized application error risk, setting new standards for ophthalmic care.
- The Federal Court of Australia denied Regeneron and Bayer's preliminary injunction application against Sandoz's aflibercept biosimilars, allowing the launch of Afqlir and Enzeevu to proceed as planned. - Justice Rofe found insufficient likelihood of patent infringement success, ruling that dosing regimens measured in "weeks" versus "months" are not equivalent under patent claim construction principles. - The decision continues Australia's trend of refusing preliminary injunctions in pharmaceutical patent cases since 2018, with the court rejecting arguments about international price referencing effects as "speculative." - Sandoz's biosimilar launch will trigger a 25% PBS price reduction for Eylea 2mg, but the court noted Regeneron was already cannibalizing its own market through transition to Eylea 8mg.
- Formycon AG successfully completed patient enrollment for its Dahlia pharmacokinetic study with 96 participants, comparing biosimilar candidate FYB206 to Keytruda in melanoma patients. - The FDA approved a streamlined clinical development program allowing Formycon to skip the Phase III trial, accelerating development and reducing costs significantly. - Results from the primary endpoint are expected in Q1 2026, with potential market entry after Keytruda's exclusivity expires in 2029 for the US and 2030 for the EU. - The development targets the world's best-selling drug with $29.5 billion in 2024 sales, potentially reaching over $50 billion by 2032.
- Formycon AG has entered into a distribution agreement with Teva's subsidiary Ratiopharm for the semi-exclusive commercialization of its Stelara biosimilar FYB202, branded as Fymskina, in Germany. - The market launch for Fymskina is scheduled for the third quarter of 2025, with Formycon handling manufacturing and supply while Ratiopharm manages commercialization. - Fymskina has already received European Commission approval for treating moderate to severely active Crohn's disease, moderate to severe plaque psoriasis, and active psoriatic arthritis. - This partnership represents Formycon's strategic approach to expand market coverage through semi-exclusive partnerships, building on its existing global commercialization agreement with Fresenius Kabi.
- Valorum Biologics LLC has secured exclusive commercialization rights for FYB203/AHZANTIVE®, Formycon's biosimilar to Eylea®, in the United States and Canada through a licensing agreement with Klinge Biopharma GmbH. - The FDA-approved biosimilar treats serious retinal diseases including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema following retinal vein occlusion by inhibiting VEGF. - Formycon will participate in mid-single-digit to low-double-digit percentage range of all payment streams and manage the supply chain, while Canadian regulatory approval is expected by the end of 2024. - The partnership leverages Valorum's experienced management team with proven track records at major pharmaceutical companies including Johnson & Johnson, Merck, and Roche to maximize market penetration.
- Formycon AG announced plans to issue a four-year corporate bond with a target volume of €50 million to fund the development and expansion of its biosimilar product portfolio. - The unsecured floating rate bond carries an interest rate based on three-month EURIBOR plus a 7.0% to 7.5% margin, with proceeds supporting the company's transition from development to commercial focus. - The public offering will be available in Germany, Luxembourg, and Austria, with subscription periods running from June 18-30, 2025, marking Formycon's first use of debt capital financing. - The company currently has three FDA and EMA-approved biosimilars including FYB201/ranibizumab already marketed in Europe and the USA, with four additional candidates in development targeting a biosimilar market projected to reach $74 billion by 2030.
- Brazil's regulatory authority ANVISA has granted marketing authorization for Ranivisio (FYB201), marking the first approved Lucentis biosimilar in the country with launch expected in Q4 2025. - Formycon has established a commercialization partnership with Brazilian pharmaceutical company Biomm to distribute the ranibizumab biosimilar in Brazil's BRL 374 million annual anti-VEGF therapy market. - The approval initiates a phased Latin American rollout, with marketing authorizations already secured in Peru, El Salvador, Honduras, and the Dominican Republic, and further launches planned through early 2027.
